Quarterly report · Q2
6960.TEDINET S100S7MX
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥134.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥62.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥14.0bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥11.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥14.1bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥25.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥14.3bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥11.8bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥9.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥8.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥9.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥8.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥210.8bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥206.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥196.9bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥39.3bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥43.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥171.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥163.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥155.1bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥70.5bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥68.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥67.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥63.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥61.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥10.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥324.32 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥208.78 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥571.25 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥268.43 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥174.15 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.8% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥20.5bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥20.5bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥737m |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.0bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥66.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥66.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.1bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥17.1bn |
| jpcrp040300-q2r_E02304-000Consumables And Other Productsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E02304-000Medical Treatment Equipmentreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E02304-000Patient Monitoring Equipmentreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥881m |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| jpcrp040300-q2r_E02304-000Physiological Diagnostic Equipmentreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥62.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥62.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes paid ope cf | Prior1YTDDuration | -4385000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -5426000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 11287000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 10385000000 | JPY |
| Decrease increase in time deposits inv cf | Prior1YTDDuration | -0 | JPY |
| Decrease increase in time deposits inv cf | CurrentYTDDuration | 2000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -5490000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -4500000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -241000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -97000000 | JPY |
| Purchase of short term and long term investment securities inv cf | Prior1YTDDuration | -1509000000 | JPY |
| Purchase of short term and long term investment securities inv cf | CurrentYTDDuration | -650000000 | JPY |
| Proceeds from sales and redemption of short term and long term investment securities inv cf | Prior1YTDDuration | 613000000 | JPY |
| Proceeds from sales and redemption of short term and long term investment securities inv cf | CurrentYTDDuration | － | JPY |
| Purchase of insurance funds inv cf | Prior1YTDDuration | -950000000 | JPY |
| Purchase of insurance funds inv cf | CurrentYTDDuration | -894000000 | JPY |
| Proceeds from maturity of insurance funds inv cf | Prior1YTDDuration | 942000000 | JPY |
| Proceeds from maturity of insurance funds inv cf | CurrentYTDDuration | 1258000000 | JPY |
| Other net inv cf | Prior1YTDDuration | 109000000 | JPY |
| Other net inv cf | CurrentYTDDuration | 53000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -6526000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -4830000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 50000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 50000000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YTDDuration | 5000000 | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYTDDuration | 4000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -0 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -3006000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -3048000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -153000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -169000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -3104000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -3162000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 593000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 159000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 2249000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 2552000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 61030000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 64939000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | Prior1YTDDuration | 140000000 | JPY |
| Increase in cash and cash equivalents resulting from merger with unconsolidated subsidiaries cce | CurrentYTDDuration | － | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 63421000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 67491000000 | JPY |
| Directors compensations salaries and allowances sga | Prior1YTDDuration | 8383000000 | JPY |
| Directors compensations salaries and allowances sga | CurrentYTDDuration | 8682000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 2256000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 2301000000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 30000000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 20000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |